肠道微生物群在肝细胞癌发病机制中的作用

郑微; 张永宏; 赵艳

doi:10.3969/j.issn.1001-5256.2019.07.041

肠道微生物群在肝细胞癌发病机制中的作用

DOI: 10.3969/j.issn.1001-5256.2019.07.041

首都医科大学附属北京佑安医院临床检验中心

基金项目:

北京市医院管理局重点医学专业发展计划(ZYLX201711);北京市医院管理局“登峰”人才培养计划(DFL20181701)；传染病相关疾病生物标志物北京市重点实验室(BZ0373)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1208
- HTML全文浏览量: 37
- PDF下载量: 343
- 被引次数: 0
出版历程
- 收稿日期: 2019-03-01
- 出版日期: 2019-07-20

Role of intestinal microflora in the pathogenesis of hepatocellular carcinoma

Clinical Laboratory Center, Beijing YouAn Hospital, Capital Medical University

Research funding:

摘要

摘要: 肝细胞癌（HCC）是最常见的原发性肝癌,是慢性肝病的并发症之一。最近的实验和临床研究表明,肠-肝轴的改变在慢性肝病（包括HCC）的发病中起关键作用。肠道微生物群的改变越来越被认为是促进慢性肝病进展为HCC的关键因素。总结了与HCC相关的肠道微生物菌群变化的最新发现,并讨论了肠道微生物群对HCC发生发展的重要意义。
- 肠-肝轴 /
- 肝肿瘤 /
- 胃肠道微生物组
Abstract: Hepatocellular carcinoma ( HCC) is the most common type of primary liver cancer and is one of the complications of chronic liver diseases. Recent experimental and clinical studies have shown that the gut-liver axis plays a key role in the pathogenesis of chronic liver diseases including HCC. Change in intestinal microflora is considered the key factor for the progression of chronic liver diseases to HCC.This article summarizes the latest research advances in changes in intestinal microflora associated with HCC and discusses the importance of intestinal microflora in the development and progression of HCC.
- intestinal hepatic axis /
- liver neoplasms /
- gastrointestinal microbiome

HTML全文

参考文献(37)

[1]MARCON PDS, TOVO CV, KLIEMANN DA, et al.Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfected with the human immunodeficiency virus:A retrospective cohort study[J].World JGastroenterol, 2018, 24 (5) :613-622.

[2]CASTVEN D, FISCHER M, BECKER D, et al.Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas[J].Oncotarget, 2017, 8 (30) :48688-48700.

[3]PENNISI E.Cancer therapies use a little help from microbial friends[J].Science, 2013, 342 (6161) :967-971.

[4]TREMAROLI V, BACKHED F.Functional interactions between the gut microbiota and host metabolism[J].Nature, 2012, 71 (7415) :242-249.

[5]CONLON MA, BIRD AR.The impact of diet and lifestyle on gut microbiota and, human health[J].Nutrients, 2015, 7 (1) :17-44.

[6]SEKI E, SCHNABL B.Role of innate immunity and the microbiota in liver fibrosis:Crosstalk between the liver and gut[J].J Physiol, 2012, 590 (3) :447-458.

[7]COMPARE D, COCCOLI P, ROCCO A, et al.Gut-liver axis:The impact of gut microbiota on non alcoholic fatty liver disease[J].Nutr Metab Cardiovasc Dis, 2012, 22 (6) :471-476.

[8]CHASSAING B, ETIENNE-MESMIN L, GEWIRTZ AT.Microbiota-liver axis in hepatic disease[J].Hepatology, 2014, 59 (1) :328-339.

[9]SZABO G.Gut-liver axis in alcoholic liver disease[J].Gastroenterology, 2015, 148 (1) :30-36.

[10]SCHNABL B, BRENNER DA.Interactions between the intestinal microbiome and liver diseases[J].Gastroenterology, 2014, 146 (6) :1513-1524.

[11]LLORENTE C, SCHNABL B.The Gut microbiota and liver disease[J].Cel Mol Gastroenterol Hepatol, 2015, 1 (3) :275-284.

[12]HUANG R, NI JJ, GAO Y.The association between the intestinal microbiota-lipopolysaccharide-Toll-like receptor 4 axis and hepatocellular carcinoma[J].J Clin Hepatol, 2018, 34 (6) :1325-1328. (in Chinese) 黄蓉, 倪加加, 高毅.肠道菌群-脂多糖-Toll样受体4轴与肝细胞癌的关系[J].临床肝胆病杂志, 2018, 34 (6) :1325-1328.

[13]MITTAL S, EL-SERAG HB.Epidemiology of hepatocellular carcinoma:Consider the population[J].J Clin Gastroenteroly, 2013, 47 (Suppl) :s2-s6.

[14]ZHANG HL, YU LX, YANG W, et al.Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats[J].J Hepatol, 2012, 57 (4) :803-812.

[15]DAPITO D, MENCIN A, GWAK GY, et al.Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4[J].Cancer Cell, 2012, 21 (4) :504-516.

[16]REN Z, LI A, JIANG J, et al.Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma[J].Gut, 2018, 68 (6) :1014-1023.

[17]PANT K, SARAYA A, VENUGOPAL SK.Oxidative stress plays a key role in butyrate-mediated autophagy via Akt/m TORpathway in hepatoma cells[J].Chem Biol Interact, 2017, 273:99-106.

[18]DARNAUD M, FAIVRE J, MONIAUX N.Targeting gut flora to prevent progression of hepatocellular carcinoma[J].J Hepatol, 2013, 58 (2) :385-387.

[19]YANG J, ZHANG JX, WANG H, et al.Hepatocellular carcinoma and macrophage interaction induced tumor immunosuppression via Treg requires TLR4 signaling[J].World J Gastroenterol, 2012, 18 (23) :2938-2947.

[20]EIRO N, ALTADILL A, JUAREZ L M, et al.Toll-like receptors3, 4 and 9 in hepatocellular carcinoma:Relationship with clinicopathological characteristics and prognosis[J].Hepatol Res, 2014, 44 (7) :769-778.

[21]LIU WT, JING YY, YU GF, et al.Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma[J].Cancer Letters, 2015, 358 (2) :136-143.

[22]WANG L, ZHU R, HUANG Z, et al.Lipopolysaccharide-induced toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma[J].Dig Dis Sci, 2013, 58 (8) :2223-2236.

[23]HOU J, LU Y, ZHANG DK.Association between intestinal dysbacteriosis and liver diseases[J].J Clin Hepatol, 2018, 34 (5) :1128-1132. (in Chinese) 候静, 路越, 张德凯.肠道菌群失调与肝脏疾病的关系[J].临床肝胆病杂志, 2018, 34 (5) :1128-1132.

[24]YANG J, LI M, ZHENG QC.Emerging role of Toll-like receptor 4 in hepatocellular carcinoma[J].J Hepatocell Carcinoma, 2015, 2:11-17.

[25] DAPITO DH, MENCIN A, GWAK GY, et al.Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4[J].Cancer cell, 2012, 21 (4) :504-516.

[26]ZHANG Z, WANG D, QIAO S, et al.Metabolic and microbial signatures in rat hepatocellular carcinoma treated with caffeic acid and chlorogenic acid[J].Sci Rep, 2017, 7 (1) :4508.

[27]YAMADA S, TAKASHINA Y, WATANABE M, et al.Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice[J].Oncotarget, 2018, 9 (11) :9925-9939.

[28]YOSHIMOTO S, LOO TM, ATARASHI K, et al.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J].Nature, 2013, 499 (7456) :97-101.

[29]TONG LC, WANG Y, WANG ZB, et al.Propionate ameliorates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress[J].Front Pharmacol, 2016, 7:253.

[30]LI J, SUNG CY, LEE N, et al.Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice[J].Proc Natl Acad Sci U S A, 2016, 113 (9) :e1306-e1315.

[31]BINDELS LB, PORPORATO P, DEWULF EM, et al.Gut microbiota-derived propionate reduces cancer cell proliferation in the liver[J].Br J Cancer, 2012, 107 (8) :1337-1344.

[32]ZHOU SL, ZHOU ZJ, HU ZQ, et al.Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib[J].Gastroenterology, 2016, 150 (7) :1646-1658.

[33]CHEW V, CHEN J, LEE D, et al.Chemokine-driven lymphocyte infiltration:An early intratumoural event determining longterm survival in resectable hepatocellular carcinoma[J].Gut, 2012, 61 (3) :427-438.

[34]HU Z, LUO D, WANG D, et al.IL-17 Activates the IL-6/STAT3 signal pathway in the proliferation of hepatitis B virusrelated hepatocellular carcinoma[J].Cell Physiol Biochem, 2017, 43 (6) :2379-2390.

[35]YE J, LIVERGOOD RS, PENG G.The role and regulation of human Th17 cells in tumor immunity[J].Am J Pathol, 2013, 182 (1) :10-20.

[36]GAO C.Molecular pathological epidemiology in diabetes mellitus and risk of hepatocellular carcinoma[J].World J Hepatol, 2016, 8 (27) :1119-1127.

[37]OGINO S, NISHIHARA R, VANDERWEELE TJ, et al.Review article:The role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine[J].Epidemiology, 2016, 27 (4) :602-611.

施引文献

资源附件(0)

访问统计